Answers are grounded in this paper and cite their sources.
Phytochemical analysis demonstrates novel lanostane triterpenoids from Kadsura coccinea inhibiting Hsp90 through non-N-terminal binding, highlighting a new class of therapeutic scaffolds.
Twenty new lanostane triterpenoids, kadsuracoccinins A–T (1–20, respectively), were isolated from the stems of Kadsura coccinea, with compounds 1–7 constituting four new carbon scaffolds elucidated by NMR analysis, X-ray diffraction, GEMSTONE-NOE-aided fc-rDG/DDD, and ECD calculations. Luciferase-refolding, NMR STD, and SPR assays revealed compounds 4 and 8–10 as the first lanostane-type Hsp90 inhibitors, which bind Hsp90 through non-N-terminal modes, with compound 8 exhibiting a KD of 4.04 μM.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: